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ABSTRACT
Objectives: Computer-administered cognitive–
behavioural therapy (CCBT) may be a promising
treatment for adolescents with depression, particularly
due to its increased availability and accessibility. The
feasibility of delivering a randomised controlled trial
(RCT) comparing a CCBT program (Stressbusters) with
an attention control (self-help websites) for adolescent
depression was evaluated.
Design: Single centre RCT feasibility study.
Setting: The trial was run within community and
clinical settings in York, UK.
Participants: Adolescents (aged 12–18) with low
mood/depression were assessed for eligibility, 91 of
whom met the inclusion criteria and were consented
and randomised to Stressbusters (n=45) or websites
(n=46) using remote computerised single allocation.
Those with comorbid physical illness were included but
those with psychosis, active suicidality or postnatal
depression were not.
Interventions: An eight-session CCBT program
(Stressbusters) designed for use with adolescents with
low mood/depression was compared with an attention
control (accessing low mood self-help websites).
Primary and secondary outcome measures:
Participants completed mood and quality of life
measures and a service Use Questionnaire throughout
completion of the trial and 4 months post
intervention. Measures included the Beck Depression
Inventory (BDI) (primary outcome measure), Mood
and Feelings Questionnaire (MFQ), Spence Children’s
Anxiety Scale (SCAS), the EuroQol five dimensions
questionnaire (youth) (EQ-5D-Y) and Health Utility
Index Mark 2 (HUI-2). Changes in self-reported
measures and completion rates were assessed by
treatment group.
Results: From baseline to 4 months post intervention,
BDI scores and MFQ scores decreased for the
Stressbusters group but increased in the website
group. Quality of life, as measured by the EQ-5D-Y,
increased for both groups while costs at 4 months
were similar to baseline. Good feasibility outcomes
were found, suggesting the trial process to be feasible
and acceptable for adolescents with depression.
Conclusions: With modifications, a fully powered RCT
is achievable to investigate a promising treatment for
adolescent depression in a climate where child mental
health service resources are limited.
Trial registration number: ISRCTN31219579.
INTRODUCTION
Rates of adolescent depression appear to be
rising1 2 with the 1-year prevalence suggested
to be between 2–4%.3 4 Early treatment is
important because adolescent depression has
high levels of future morbidity including
further emotional disorders, suicidality, phys-
ical health problems, substance misuse and
problems in social functioning.4 5
Research examining antidepressant medi-
cation for treating adolescents with depres-
sion has been mixed. A meta-analysis6
including two randomised controlled trials
(RCTs) comparing antidepressants and cog-
nitive–behavioural therapy (CBT)7 8 found
no statistically signiﬁcant differences between
antidepressants and CBT for the majority of
outcomes, including no differences between
Strengths and limitations of this study
▪ The study explores the feasibility of using a
range of mental health and health economics
measures in a population of adolescents with
low mood.
▪ The study produces important feasibility infor-
mation to inform a fully powered randomised
controlled trial.
▪ Feasibility data on acceptability, completion rates
and attrition are examined.
▪ The sample of participants is obtained from only
one National Health Service Trust resulting in
potential bias.
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the groups on self-rated depression symptoms post inter-
vention or at 6–9 months follow-up. Signiﬁcantly, fewer
participants had suicidal ideation in the CBT group
than the antidepressant group at post intervention and
at 6–9 month follow-up. Although antidepressants clearly
have an important place in a stepped-care approach, the
National Institute for Health and Care Excellence
(NICE) Guidelines (2015)9 state that they should not be
used for the initial treatment of children and adoles-
cents with mild depression. Thus, provision of talking
therapies (ie, CBT) is an important area for research
and practice.
Reviews of CBT for adolescent depression show that it
is effective and currently one of the main treatment
options recommended for this group.10 11 Trials com-
paring CBT to family therapy or supportive psychother-
apy suggests it is better at improving mood and
achieving remission.12 It has also been shown to
prevent depression in high-risk adolescent groups,
including the offspring of depressed adults.13 With a
low side-effect proﬁle, CBT is an attractive option for
treating adolescent depression. Despite this and recent
government focus on improving access to psychological
therapies, reduced staff numbers in Child and
Adolescent Mental Health Services (CAMHS) make
CBT delivery challenging, especially in a context where
local authority and National Health Service (NHS)
child services funding is tight.
Despite the evidence base for the effectiveness of CBT
for adolescent depression,10 14 15 adolescents often avoid
face-to-face therapy because of stigma.16 Given their
afﬁnity with computers, treatment accessibility may be
improved by the availability of computer-administered
CBT (CCBT) which could be provided at an earlier
stage of illness,17 particularly for those with a high
degree of familiarity with technology.18 CCBT represents
an autonomous form of therapy delivery with the poten-
tial to provide a realistic alternative, or potentially pre-
ventative, intervention.
A systematic review19 found six studies examining
CCBT for adolescent depression. Only three were RCTs
and none were conducted in the UK. Although the
countries where this research occurred (USA,20 21
Australia22 23 and Holland24) may be culturally similar to
the UK, differences on a systemic level (eg,
mental healthcare provision) as well as on a societal
level (eg, language use, norms) mean their results
cannot be generalised to a UK population. To date,
although current literature suggests potential beneﬁts of
CCBT for adolescents with low mood/depression,25
more RCTs need to be conducted with depressed
adolescents in the UK.
The UK-developed CCBT package Stressbusters
showed positive results in a case series17 where 95% of a
UK adolescent sample met diagnostic criteria for depres-
sion at baseline, falling to 22% post treatment. This,
alongside good completion rates (70% completing all
eight sessions), suggests that Stressbusters is a potentially
effective CCBT package warranting further investigation
within an RCT.
More recently, an RCT examining the effectiveness of
Stressbusters within a school setting was conducted.26
The study showed a signiﬁcant reduction in adolescent
depression and anxiety compared with a waiting list
control. However, more research is required to examine
the effectiveness of CCBT in comparison to an attention
control to ensure any effects observed are a result of the
CCBT intervention.
We aimed to assess the feasibility of delivering an RCT
comparing Stressbusters (CCBT) with an attention
control (accessing low mood self-help websites) for ado-
lescents with low mood/depression to establish:
▸ the feasibility of recruiting adolescents with low
mood/depression;
▸ the feasibility of delivering CCBT as a treatment for
adolescents including retention rates, compliance
with the CCBT program, completion rates for
outcome measures and withdrawal from interven-
tion/trial rates;
▸ the parameters, outcomes and cost-effectiveness of
the study to inform a full-scale RCT.
METHODS
Participants and recruitment
Our target population was 12–18-year olds with low
mood/depression living within the areas covered by a
CAMH service in a Northern City in England.
Trial referrals were made by nine Primary Mental
Health Workers (PMHWs) who screened adolescents
referred to them with low mood/depression. Young
people gave fully informed consent (with that of their
parent/guardian if under 16). Eligibility was deﬁned by
a score of ≥20 on the Mood and Feelings Questionnaire
(MFQ)27 (validation research28 proposes a score of ≥20
indicates any depressive disorder and ≥29 a likely
current major depressive episode). Those with comorbid
physical illness were included but those with psychosis,
active suicidality or postnatal depression were not. Those
with severe depression were referred to the local
CAMHS team for assessment and treatment in the ﬁrst
instance, clinicians then decided whether trial participa-
tion would be suitable for them.
Study design and methodology
The study was conducted between June 2011 and
December 2014. Consented participants attended a
baseline visit with the researchers where they completed
the following measures:
Short Beck Depression Inventory (BDI) (primary outcome
measure)
A 13-item self-reported measure used to assess depres-
sion severity among adolescents by measuring cognitive,
behavioural, affective and somatic dimensions of
depression.29
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Mood and Feelings Questionnaire (MFQ)
A 33-item questionnaire, based on Diagnostic and
Statistical Manual of Mental Disorders (DSM-III-R) cri-
teria for depression, comprising descriptive phrases
regarding how an individual has been feeling or acting
in the preceding 2 weeks.27 A Cronbach’s α of 0.95 for
the MFQ has been reported28 suggesting high internal
consistency.
Spence Children’s Anxiety Scale (SCAS)
A 45-item, self-report measure used to assess the severity
of anxiety within six subgroups (generalised anxiety,
panic/agoraphobia, social phobia, separation anxiety,
obsessive–compulsive disorder and physical injury fears)
alongside providing an overall anxiety score.30 An ana-
lysis of the internal consistency of the SCAS31 produced
a coefﬁcient α of 0.92 and a Guttman split half reliability
of 0.90.
Quality of life (QoL), including the EQ-5D-Y and HUI-2,
and service use questionnaire
Self-report questionnaires were used to obtain informa-
tion about health-related QoL and service use. This
comprised: (1) the EuroQol EQ-5D-Y32 and (2) Health
Utility Index Mark 2 (HUI-2), both instruments for cap-
turing health-related QoL in young people,33 and (3) a
Service Use Questionnaire at individual level. The
Service Use Questionnaire collected data on the follow-
ing services: (1) consultation with the general practi-
tioner (GP) or nurse at home, surgery or by telephone;
(2) other community health service use, including
CAMHS, clinical psychologist, community psychiatric
nurse, counsellors, family therapist, social worker and
helplines (eg, MIND, Childline); (3) hospital-based ser-
vices, including psychiatric or non-psychiatric appoint-
ments, psychiatric and non-psychiatric admissions and
emergency attendances (including Accident and
Emergency attendance) and (4) use of medication.
Preference scale (treatment allocation)
A preference scale was used to determine participant
preference for the trial arm they would like to complete
if the research did not involve randomisation. This was
completed by participants at the baseline visit.
Participants were asked to complete a scale (0–100) to
indicate their preference for either Stressbusters (100),
websites (0) or no preference (50). Participants were
informed that their responses on this scale would have
no impact on trial allocation.
Demographic information
Participants were asked to supply demographic informa-
tion including their age, gender and ethnicity, their edu-
cation and employment status and their family life and
social relationships.
Following the completion of baseline measures, parti-
cipants were randomised to one of two trial arms using
remote computerised single allocation (provided by the
University of York Trials Unit). The trial arms were as
follows:
Arm 1: CCBT intervention: ‘Stressbusters’
Stressbusters is a CCBT program comprising eight 30–
45 min sessions of CBT designed for 12–18-year olds.
The program is based on the manualised treatment pro-
gramme from an RCT designed to evaluate the effective-
ness of CBT compared with a placebo control.34 Each
Stressbusters session is an interactive presentation featur-
ing videos, animations, graphics and printouts.
Sessions are completed in linear progression with
each building on knowledge gained in previous sessions
and tasks carried out at home between sessions.
Homework tasks typically involved the completion of
mood diary sheets, with compliance measured by young
people entering whether they had completed the tasks
into the Stressbusters program at their next session.
Sessions contain ﬂexible ‘add-ons’ such as written fact
sheets (eg, about bullying, sleep problems) which
can be printed out and taken home alongside
practice-related hand-outs from the program (eg, mood
diary sheets).
Video inserts (case vignettes) of three teenagers
feature throughout. Participants hear about the lives of
the teenagers and watch them themselves using the
program in a combination of short video sequences and
voiceovers. The participant inputs information (eg,
mood ratings, activity plans, quiz answers, etc) which is
stored and used throughout the program.
The session content is organised into the following:
Session 1: Introduction to the program and goal setting
Session 2: Getting activated
Session 3: Emotional recognition
Session 4: Noticing thoughts
Session 5: Thought challenging
Session 6: Problem solving
Session 7: Improving social skills
Session 8: Relapse prevention.
Arm 2: attention control: self-help websites
Participants in arm 2 spent an equivalent time accessing
currently available self-help websites. These were chosen
by an expert clinical panel, with user and carer involve-
ment, based on them being suitable for use with the par-
ticipant age range, not being heavily laden with
information about self-harm and having no or minimal
CBT content. All selected websites provided information
about low mood/depression in a combination of texts,
narratives and videos. These were:
http://www.youngminds.org.uk
http://www.depressioninteenagers.com
http://www.RU-OK.org.uk
http://www.healthtalk.org
Participants were introduced to a new website at each
of the ﬁrst four sessions. After introduction of all four
websites they could spend subsequent sessions returning
to the sites/areas that they found most helpful.
Wright B, et al. BMJ Open 2017;7:e012834. doi:10.1136/bmjopen-2016-012834 3
Open Access
Procedure
A researcher met individual participants at each session
to provide instructions and practical support with acces-
sing the computer but did not provide any therapy.
Participants were offered a choice of venue to complete
trial sessions; including their school, CAMHS site, GP
surgery or community centre. All sites provided private
spaces that protected conﬁdentiality. Sessions were typic-
ally once per week with ﬂexibility offered to ﬁt around
participants’ other commitments. The methodology is
described in more detail elsewhere.35
Participants completed a modiﬁed version (15 items)
of the MFQ36 at the beginning of each session to
monitor mood and assess risk as adopted in the Abeles
et al17 study. If a participant responded ‘true’ to the
question ‘I thought about killing myself’ on the short
MFQ their PMHW/CAMHS clinician was contacted
immediately and asked to speak with the individual to
discuss their response. If a PMHW/CAMHS clinician
was unavailable, this request was made to the duty clin-
ician. Where none of the above could be contacted, the
individual was advised to contact their GP. (This proced-
ure also applied if a participant selected ‘true’ to the
same question on the full MFQ or selected the response
‘I have deﬁnite plans about committing suicide’ or ‘I
would kill myself if I had the chance’ during any com-
pletion of the BDI). No serious incidents took place
during the trial.
The MFQ, BDI, SCAS and QoL/Service Use
Questionnaire were then subsequently completed at 4
and 12 months after completion/withdrawal from the
intervention (results of the 12-month follow-ups will be
reported separately).
The acceptability of the trial and its processes were
evaluated through face-to-face qualitative interviews with
20 participants. Interviews followed a topic guide to
ensure consistency and included experiences of depres-
sion, care pathways, responses to depressive symptoms,
acceptability of treatment/location and priority out-
comes (ie, what individuals hoped their participation
would achieve). These results will be reported in a subse-
quent publication.
Sample size
No formal power calculations are undertaken in feasibil-
ity studies; rather sufﬁcient participants are recruited to
determine factors such as recruitment and attrition rates
in relation to feasibility outcomes.37 However, in the
initial planning stages, we based our sample size on pre-
vious work examining the Stressbusters program in 28
young people.17 Here, 70% of participants who com-
pleted at least one session of Stressbusters continued
with the program and completed all eight sessions. We
calculated that, to detect a difference of 10 points post
treatment on the MFQ between the two groups at 80%
power and 5% signiﬁcance, 26 participants per group
were required: 48 per group (n=96) to allow for those
not completing treatment. We were therefore fully
powered for the MFQ but had no power calculation for
the BDI or other outcome measures selected, and no
pre-existing feasibility data or attrition and acceptability
data for computerised therapy. Hence, the reason for
this feasibility study.
Data analysis
Feasibility data included: number of eligible participants,
willingness of clinicians to recruit and young people to
participate, adherence to interventions and completion
of outcome measures including follow-up, time needed
to collect data and SDs of the outcome measures to esti-
mate sample size for a full-scale RCT. Treatment adher-
ence was calculated as the percentage of participants in
the Stressbusters group completing all eight sessions,
and of the website group completing all four websites
over a minimum of four sessions. Data are summarised
for the baseline characteristics using means (SD),
medians (IQR) and n (%) for the each of the outcome
measures (BDI, SCAS, MFQ).
Consistent with recommendations about good practice
in the analysis of feasibility studies38 feasibility analysis
was descriptive with descriptive statistics calculated for
follow-up rates, withdrawal from intervention/trial rates
and adherence. Summary statistics were also calculated
for the outcome measures (BDI, MFQ and SCAS) at base-
line and 4 months follow-up. Analyses were performed in
SPSS (V.21). Completion rates of the EQ-5D-Y,32 HUI-233
and Service Use Questionnaires were assessed. Changes
in costs and outcomes were combined in the form of
Incremental Cost Effectiveness Ratio (ICER) and the
uncertainty in ICER was estimated. Full details of the eco-
nomic analysis will be reported separately.
RESULTS
Overall 136 individuals were assessed for eligibility.
Thirty-eight did not meet the inclusion criteria and
seven declined to participate. Ninety-one young people
consented and were randomised to either Stressbusters
(n=45) or websites (n=46) (see CONsolidated Standards
Of Reporting Trials (CONSORT) Statement diagram in
ﬁgure 1).
Feasibility outcomes
The groups were similar in age, but the Stressbusters
group had a lower proportion of males (27%) than the
website group (41%). More individuals in the websites
group had physical health problems (22%) than the
Stressbusters group (4%). A higher proportion of the
Stressbusters group were currently or had been bullied
(83%) than the websites group (72%) and were more
likely to occasionally use alcohol (62% vs 41%). Similar
proportions in each arm had previously sought help
with low mood (table 1).
At 4 months post intervention, self-report question-
naires were sent to 41/45 (91%) participants in the
Stressbusters group and 42/46 (91%) of participants in
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the website group (table 2). The ﬁve participants who
did not receive a follow-up questionnaire had withdrawn
completely from the trial (ﬁgure 1). The overall return
rate was 56% (25/45) for the Stressbusters group and
65% (30/46) for the website group (p=0.346). There
was no signiﬁcant difference between those who
returned their 4-month questionnaire (n=55) and those
who did not (n=36) by age (15.2 (1.4) vs 15.4 (1.3),
p=0.690) or gender (male: 40% vs 25%, p=0.140).
Adherence to treatment was calculated in both
groups; 62% (28/45) of participants in the Stressbusters
group completed all eight sessions, and 76% (35/46) of
participants in the website group completed all four
websites. Overall, 8/91 (9%) participants did not com-
plete any treatment sessions (four randomised to
Stressbusters and four to websites) (table 3).
The length of time between key dates in the partici-
pants’ journeys throughout the trial was similar between
groups (table 4). The mean time from randomisation to
the start of intervention was 19.6 days. The average dur-
ation of the intervention was 54.6 days in the
Stressbusters group and 49.9 days in the website group.
Overall the average number of days between randomisa-
tion and sending out a 4-month follow-up questionnaire
was 209.8 days while return of the questionnaire took an
average of 9.6 days.
Table 1 Baseline characteristics
Stressbusters (45) Websites (46)
Age at baseline (mean (SD)) 15.5 (1.4) 15.2 (1.2)
Gender (male) 12 (27%) 19 (41%)
Ethnic group (white) 45 (100%) 45 (98%)
Do you consider yourself to have any physical health problems? (yes) 2 (4%) 10 (22%)
Have you ever been bullied?
I am currently being bullied 3 (7%) 6 (13%)
I have been bullied in the past but not at the moment 34 (76%) 27 (59%)
I have never been bullied 8 (18%) 12 (26%)
Missing 0 (0%) 1 (2%)
Do you drink alcohol?
Never 17 (38%) 27 (59%)
Occasionally 28 (62%) 19 (41%)
Frequently 0 (0%) 0 (0%)
Have you previously experienced any episodes of low mood? (yes) 42 (93%) 42 (91%)
Do you seek help to deal with your low mood? (yes) 31 (72%) 29 (69%)
Have you ever been prescribed antidepressants?
Yes 4 (9%) 2 (4%)
No 33 (73%) 29 (63%)
Not applicable 8 (18%) 15 (33%)
CBT in the past (yes) 10 (22%) 10 (22%)
Counselling in the past (yes) 16 (36%) 15 (33%)
Other talking therapies in the past (yes) 4 (9%) 1 (2%)
CBT, cognitive–behavioural therapy.
Table 2 Completion rates for questionnaires across trial time points
CCBT group Websites group Total
Time point Measure Distributed Completed Distributed Completed Distributed Completed
Baseline MFQ 45 45 (100%) 46 46 (100%) 91 91 (100%)
BDI 45 45 (100%) 46 46 (100%) 91 91 (100%)
SCAS 45 45 (100%) 46 46 (100%) 91 91 (100%)
EQ-5D-Y 33 33 (100%) 35 34 (97%) 68 67 (98.5%)
HUI 33 33 (100%) 35 35 (100%) 68 68 (100%)
Service Use 33 33 (100%) 35 35 (100%) 68 68 (100%)
4-month follow-up MFQ 41 25 (60.9%) 42 30 (71.4%) 83 55 (68.3%)
BDI 41 25 (60.9%) 42 30 (71.4%) 83 55 (68.3%)
SCAS 41 25 (60.9%) 42 30 (71.4%) 83 55 (68.3%)
EQ-5D-Y 41 25 (60.9%) 42 28 (66.7%) 83 53 (63.9%)
HUI 41 25 (60.9%) 42 30 (71.4%) 83 55 (68.3%)
Service Use 41 25 (60.9%) 42 30 (71.4%) 83 55 (68.3%)
BDI, Beck Depression Inventory; CCBT, computer-administered cognitive–behavioural therapy; EQ-5D-Y, EuroQol five dimensions
questionnaire (youth); HUI, Health Utility Index; MFQ, Mood and Feelings Questionnaire; SCAS, Spence Children’s Anxiety Scale.
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Outcome measures
Table 5 shows the scores for those who completed the
BDI, MFQ, SCAS (total and subscale scores) and the
QoL and Service Use Questionnaire at baseline and
4 months. Higher scores on the BDI, MFQ and SCAS
represent greater levels of depressive (BDI, MFQ) or
anxiety (SCAS) symptoms.
There was no statistically signiﬁcant difference
between those who returned their 4-month question-
naire and those who did not in the baseline BDI (15.9
(7.3) vs 17.5 (7.1), p=0.303), MFQ (35.7 (9.4) vs 36.2
(8.6), p=0.820) or SCAS total scores (43.8 (17.) vs 41.5
(17.5), p=0.548).
The mean MFQ scores fell by 6.7 (15.5) in the
Stressbusters group, while website group scores increased
by 1.7 (11.5) from baseline to 4 months, a difference of
8.4. Eligibility was deﬁned by a score of ≥20 on the MFQ
at baseline. Since a score of 29 represents a likely current
major depressive episode and 20 any depressive episode,
this change difference has some clinical meaning. At
4 months, 20% (5/30) of the Stressbusters group scored
below 20 compared with 20% (6/24) in the websites
group. Hence, there was no substantial reduction in the
proportion with no evidence of a depressive disorder at
4 months. For participants completing all eight sessions
in the CCBT group, MFQ scores reduced from a mean
of 36.6 at baseline to 28.6 at 4 months.
At baseline, 86% (37/43) scored 29 or more in the
Stressbusters group which fell to 60% (15/25) at
4 months. In the websites group, 72% (33/46) scored 29
or more at baseline, falling to 63% (19/30) at 4 months.
Hence, in the Stressbusters group, there was a substantial
reduction from baseline in the proportion of participants
with a likely current major depressive episode at 4 months.
Figure 1 CCBT CONSORT flow diagram. CCBT, computer-administered cognitive–behavioural therapy.
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To ensure that participants who did not complete
4-month follow-up were not different to those who did,
only those participants for whom paired data were avail-
able were examined. In the Stressbusters group, 91%
(21/23) of participants scored 29 or more on the MFQ
at baseline which fell to 57% (13/23) at 4 months. In
the websites group, 66% (20/30) of participants scored
29 or more at baseline which fell to 63% (19/30) at
4 months. Again in the Stressbusters group, there was a
substantial reduction from baseline in the proportion of
participants with a likely current major depressive
episode at 4 months. The baseline proportions were not
signiﬁcantly different to the overall sample.
In the Stressbusters group, mean BDI scores fell by 2.8
(6.6) from baseline to 4 months, whereas the website
groups increased by 1.2 (8.5). The changes in SCAS
total scores and subgroup scores were similar between
groups, with the total score seeing a slight fall
(0.2 (13.7)) in the Stressbusters group and a slight
increase in the websites group (0.2 (10.6)). For partici-
pants completing all eight sessions in the CCBT group,
BDI scores reduced from a mean of 15.8 at baseline to
12.8 at 4 months.
Weekly session short-form MFQ scores are shown in
table 6. The Stressbusters group had high scores at visit
1 (17.4(6.5)), which reduced over the ﬁrst four sessions
to plateau after that (12.3 (7.0) at session 4). The
website group had lower scores at visit 1 (14.8(6.2))
compared with the Stressbusters group, but their scores
remained fairly consistent over the sessions (13.7 (8.0)
at session 4).
When asked about their preference for treatment,
prior to knowledge of treatment allocation, four partici-
pants indicated that websites would be their preferred
treatment if randomisation was not used, while the
remainder opted for Stressbusters (n=44) or had no
preference (n=41).
Sample size required for a full-scale RCT
To conduct a fully powered RCT of the clinical and cost-
effectiveness of CCBT, based on a 4-month return rate
of 60%, the changes in MFQ and BDI scores from base-
line to 4 months have been used to calculate sample size
requirements (table 5).
If the MFQ were the primary outcome measure, to
detect a difference of 8.4 points (pooled SD=13.37) (the
change score detected on the MFQ across both groups
in this study), at 80% power and 5% signiﬁcance, 41 par-
ticipants would be required per arm. Based on a 60%
completion rate, this represents 68 per group (a total of
136 participants).
If the BDI were the primary outcome measure, to
detect a difference of 4.0 points (pooled SD=7.70) (the
change score detected on the BDI across both groups in
this study), at 80% power and 5% signiﬁcance, 60 parti-
cipants would be required per arm. Based on a 60%
completion rate, 100 per group are required (a total of
200 participants).
The MFQ can monitor risk, has wide use in other
sudies for comparison in this age group39–41 and is the
outcome measure recommended by NICE. Thus, we
suggest that the MFQ would be the appropriate
Table 3 Summary of retention and completion of measures
Stressbusters Websites Total
Given baseline questionnaire to complete 45 46 91
Completed baseline questionnaire 45 (100%) 46 (100%) 91 (100%)
Started intervention 41 (91%) 42 (91%) 83 (91%)
Adherence to treatment:
CCBT group completing all the eight sessions,
the website group completing all four websites and at least four sessions
28 (62%) 35 (76%) 63 (69%)
Sent 4-month questionnaire 43 (96%) 43 (93%) 86 (95%)
Returned 4-month follow-up questionnaire 25 (56%) 30 (65%) 55 (60%)
CCBT, computer-administered cognitive–behavioural therapy.
Table 4 Length of time between key events in the RCT process
Stressbusters Websites Total
Number randomised 45 46 91
Number started intervention 41 42 83
Number of days from randomisation to intervention (mean (SD)) 19.8 (14.4) 19.4 (14.1) 19.6 (14.2)
Number of days from intervention start to date completed (mean (SD)) 54.6 (32.8) 49.9 (32.8) 52.2 (32.8)
Days from randomisation to 4-month questionnaire sent (mean (SD)) 205.6 (32.8) 214.0 (33.9) 209.8 (33.4)
Days from intervention date to 4-month questionnaire sent (mean (SD)) 190.1 (30.8) 196.2 (30.6) 193.2 (30.7)
Days from completion date to 4-month questionnaire sent (mean (SD)) 134.1 (30.0) 145.1 (19.5) 139.8 (25.6)
4-month returned 25 30 55
Days from sent to return—4-month questionnaire (mean (SD)) 14.9 (29.4) 5.1 (11.1) 9.6 (21.9)
RC, randomised controlled trial.
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outcome measure of choice in a larger fully powered
study.
Health economic analysis
Completion rates of the QoL and Service Use
Questionnaire were assessed and responses analysed
using STATA 13.
Completion rates for the economic questionnaire were
>60% in both groups (table 2), in terms of QoL ques-
tionnaires (ie, EQ-5D-Y and HUI) and the Service Use
Questionnaire. This was the same as other question-
naires at 4-month follow-up. The utility analysis sug-
gested small changes in both groups between baseline
and 4 months (websites: baseline =0.61 (SE: 0.10) and
4 months =0.65 (SE: 0.13); Stressbusters: baseline =0.52
(SE: 0.09) and 4 months =0.58 (SE: 0.12)). The cost of
delivering the Stressbusters program to the 45 partici-
pants allocated to receive this treatment was £4557.40,
thus indicating a provisional cost per participant of
£101.20.i The cost analysis of service use suggested that
there was a difference in mean costs at baseline between
the two groups (websites: baseline =£950 (SE=£193.1)
and 4 months =£597 (SE=£63.0)). This difference in
baseline costs is likely to be due to the small sample size
which may result in large differences in costs due to a
small number of heavy service users (as shown by the
large SE). However, more importantly, this difference in
costs between groups remained similar at 4 months
(websites: 4 months =£950 per patient (SE: £542.8);
Stressbusters: 4 months =£499 per patient (SE: £147.6)).
Baseline differences in costs and utility between groups
should be taken into account in a regression analysis to
estimate difference between groups (ie, the treatment
effect) and to calculate ICER. However, due to the small
sample size, there was not enough power to conduct a
regression analysis to adjust for baseline differences and
estimate ICER. Hence, we suggest that a fully powered
study with adequate sample size is required to conduct a
full cost-effectiveness analysis.
Funding an intervention should be based on whether
it is likely to represent value for money to the NHS. This
decision might be guided by the expected health gain
Table 5 Scores on the BDI, MFQ, SCAS, utilities (EQ-5D-Y) and costs at baseline and 4 months
Stressbusters (45) Websites (46)
Mean (SD) n Median (IQR) Mean (SD) n Median (IQR) Mean difference
MFQ
Baseline 37.0 (8.8) n=43 36.0 (31.0–41.0) 34.8 (9.1) n=46 34.0 (26.0–41.0)
4 month 32.7 (16.0) n=25 36.1 (20.6–41.0) 35.5 (16.5) n=30 43.0 (21.0–49.0)
Change −6.7 (15.5) n=23 −8 (−19, −7) 1.7 (11.5) n=30 2.5 (−7, −10) 8.4 (SE 3.7)
(95% CI 1.0 to 15.8)
BDI
Baseline 18.3 (7.4) n=42 19.5 (13.0–24.0) 14.8 (6.7) n=44 14.5 (10.0–18.5)
4 month 15.5 (9.6) n=25 16.0 (9.0–20.0) 15.5 (10.1) n=30 14.5 (7.0–25.0)
Change −2.8 (6.6) n=24 −4 (−8, −3) 1.2 (8.5) n=29 0 (−6, −8) 4.0 (SE:2.1)
(95% CI −0.3 to 8.2)
SCAS total scores
Baseline 46.7 (16.1) n=43 42.0 (35.0–62.0) 39.0 (18.5) n=43 42.0 (23.0–55.0)
4 month 46.7 (23.0) n=23 48.0 (25.0–67.0) 39.9 (22.5) n=28 37.5 (21.0–59.5)
Change −0.2 (13.7) n=21 −1.0 (−15.0, 10.0) 0.2 (10.6) n=27 −4.0 (−8.0, 8.0) 0.4 (3.5)
(95% CI −6.7 to 7.5)
Utilities (EQ-5D)
Baseline 0.53 (0.26) n=34 0.50 (0.29–0.73) 0.60 (0.33) n=33 0.73 (0.29–0.85)
4 month 0.58 (0.33) n=25 0.69 (0.38–0.85) 0.65 (0.30) n=27 0.73 (0.36–0.85
Costs (£, mean total)
Baseline 597 (351) n=31 558 (294–850) 950 (1142) n=35 414 (261–1268)
4 month 499 (708) n=23 181 (0–601) 950 (2821) n=27 164 (84–277)
BDI, Beck Depression Inventory; EQ-5D-Y, EuroQol five dimensions questionnaire (youth); MFQ, Mood and Feelings Questionnaire; SCAS,
Spence Children’s Anxiety Scale.
Table 6 Session MFQ scores (mean (SD), n)
Stressbusters Websites
Visit 1 17.4 (6.5), 41 14.8 (6.2), 42
Visit 2 15.0 (7.6), 37 13.5 (6.8), 40
Visit 3 13.8 (6.4), 34 13.3 (7.2), 37
Visit 4 12.3 (7.0), 34 13.7 (8.0), 35
Visit 5 12.5 (7.1), 31 13.8 (9.6), 24
Visit 6 13.1 (7.6), 29 14.7 (9.2), 12
Visit 7 12.7 (8.8), 28 11.3 (7.3), 8
Visit 8 11.4 (8.0), 28 12.7 (5.4), 7
MFQ, Mood and Feelings Questionnaire.
iThe licence fee had not been ﬁnalised at the time of this study and
was waivered for the trial so this ﬁgure may be an underestimate.
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required within NICE reimbursement thresholds
(£20 000–£30 000 per quality-adjusted life year (QALY)).
Based on the treatment delivery cost of Stressbusters
(assuming other service use costs are not signiﬁcantly
different between groups), the incremental QoL gain
due to Stressbusters would need to be in the range
between 0.00337 (at willingness-to-pay threshold of
£30 000 per QALY) and 0.00506 QALYs (at
willingness-to-pay threshold of £20 000 per QALY) for
the Stressbusters intervention to be cost-effective. This
implies that the Stressbusters program would need to
achieve an improvement in the overall QoL of children
by at least 0.6% to 0.8%, to be cost-effective (based on
the conventional willingness-to-pay thresholds used in
the UK).
DISCUSSION
This study aimed to assess the feasibility of delivering an
RCT comparing Stressbusters with self-help websites for
adolescents with low mood/depression. Rich informa-
tion regarding the application of CCBT as a treatment
for this group in the community (notably in schools)
has been yielded through this feasibility study.
Furthermore, reductions were seen in depression scores,
as measured by the MFQ and BDI for those who
received CCBT.
Those involved in the trial including adolescents, tea-
chers (who assisted with setting up the trial in schools) and
CAMHS clinicians (responsible for referring young people
and dealing with risk) were largely supportive of CCBT as a
treatment for adolescent depression. Recruitment was suc-
cessful within the speciﬁed time frame.
We were able to develop a strong infrastructure across
schools and the community to deliver the program.
Although, we initially set out to deliver the trial in seven
local schools, this infrastructure expanded to include 10
schools, two clinics, one GP practice and a community
centre to accommodate the needs of the young people
wanting to take part.
Clinicians were positive about the use of CCBT as a
treatment for adolescents with low mood/depression,
demonstrated through their enthusiasm in referring
young people to the trial. Schools also actively requested
access to CCBT with requests being made during the
trial period when they heard about the trial (and
schools requested involvement) and following comple-
tion of the trial (where schools requested their own
copies of the CCBT program).
Despite positive reactions to the trial only 60% of parti-
cipants returned follow-up questionnaires (despite remin-
ders) at 4 months. Although disappointing, this ﬁgure is
comparable to the 4-month follow-up return rates found
in several similar studies of computerised therapies for
adolescents with depression (eg, 51%,42 60%43). Future
studies could use improved mechanisms for collecting
follow-up data, such as electronic reminders, availability
of remote electronic data completion and small rewards
for time taken. Other studies44 suggest that these
methods can improve completion rates.
There was no signiﬁcant difference in the response
rate at 4 months between the groups or a signiﬁcant dif-
ference between those who returned their 4-month
questionnaire and those who did not by age or gender.
In addition, there was no statistically signiﬁcant differ-
ence between those who returned their 4-month ques-
tionnaire and those who did not in the baseline BDI,
MFQ or SCAS total scores. Hence, there is no evidence
that bias in the estimation of parameters is presented
(now with 95% CI for the outcome measures) due to
response bias. In addition, there is evidence that missing
data are missing completely at random (MCAR). The
statistical advantage of data that are MCAR is that the
analysis remains unbiased. Power may be lost in the
design, but the estimated parameters are not biased by
the absence of the data. Where response rates are low
for future studies, helpful methodologies could include
analysis of last observation carried forward (LOCF) or
mixed-effect model repeated measure (MMRM) analysis.
In total, 62% of participants in the CCBT group com-
pleted all eight sessions of the program. This ﬁgure
compares favourably to other studies examining compu-
terised therapies with completion rates of 39%24 and
57%.45 These ﬁgures are, however, lower than those
reported with face-to-face CBT,45 suggesting that the
presence of a clinician may encourage completion and
thus reduce attrition. It is important to note that eight
of the 91 participants who originally consented to the
trial withdrew before starting treatment. These eight
received alternative NHS treatments. We note that many
studies only include consented participants after they
have started the ﬁrst research treatment session. Our
percentage for completion of 4-month follow-up ques-
tionnaires and completion of all treatment sessions
would be improved if we reported in this way (66% and
76%, respectively). The high completion rates for self-
help websites suggest that they are acceptable to partici-
pants but no notable improvement in depression scores
took place in this group.
For participants completing all eight sessions in the
CCBT group, MFQ scores reduced from a mean of 36.6
at baseline to 28.6 at 4 months (BDI: 15.8 to 12.8). As
not all participants completed all eight sessions (62%),
this may suggest that in a treatment care pathway, some
young people may need redirecting to alternative ser-
vices (eg, face-to-face support). Research into the place
of CCBT in the care pathway is warranted.
Regular monitoring was necessary in the completion
of this study. Responses to items on the MFQ and BDI
were checked as part of this monitoring with good
responses available in the event of participants needing
additional support. The method employed here was feas-
ible to successfully support the trial and will be repeated
in any further studies we complete within this context
Our economic analysis suggests that Stressbusters is
relatively inexpensive to implement and may require
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only modest health beneﬁts to be within the NICE’s
willingness-to-pay threshold per QALY. This supports the
need for a fully powered RCT. Further economic analysis
may consider the potential to reduce the volume, costs
and length of treatment received by adolescents with low
mood/depression.
Limitations and lessons learnt
Exploring mechanisms to improve data collection in a
technological age is likely to yield higher return rates for
outcome measures. Online data collection (currently
being trialled in other local research) would potentially
make outcome measure completion quicker and easier
for participants. Currently, we are carrying out further
feasibility work to examine the collection of more com-
plete outcome measure data using increased face-to-face
research assistant time, using text message reminders
and providing appropriate ‘thank you’ rewards that do
not contravene ethical boundaries. Our original trial
timeline was based on participants completing treatment
sessions within 8 weeks (ie, one session per week). This
rarely occurred because of participant availability (eg,
examination periods) which often caused delays.
Although most participants reported that they did not
ﬁnd this problematic, this would need to be considered
in a full-scale trial.
The trial was only conducted within one NHS trust
resulting in the under-representation of certain minor-
ities and a lack of varied geographical localities and
demographic characteristics. A larger RCT would need
an extended geographical footprint that includes wider
ethnic and sociocultural diversity. Furthermore, some of
those recruited had received other services for their low
mood/depression prior to the trial. In future research, a
community sample should be recruited to investigate
the effectiveness of CCBT for those who have not
accessed services previously.
CONCLUSION
This feasibility study has provided rich information about
recruitment, attrition and acceptability of outcome mea-
sures, interventions and involvement in an RCT. These
feasibility ﬁndings and encouraging trends in cost-
effectiveness data offer encouragement to warrant a fully
powered RCT to evaluate the clinical and cost-effectiveness
of this intervention for this population. Quantitative data
have provided robust power calculations, while health eco-
nomic analysis highlights the level of uncertainty in the
ICER given small numbers and further supports a larger
study, with a larger sample, to address this.
Improvements in methodology could focus on add-
itional support for session attendance and outcome
measure completion but these are not insurmountable
challenges. For a full trial, we would recommend using
MFQ scores as the main outcome measure given that
NICE guidelines now recommend this outcome measure
for adolescent depression.
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